SUFU 突变型 Gorlin-Goltz 综合征患者行有效抗程序性死亡-1 治疗。
Effective anti-programmed death-1 therapy in a SUFU-mutated patient with Gorlin-Goltz syndrome.
机构信息
Department of Dermatology, Universitätsklinikum Erlangen, Friedrich-Alexander-University Erlangen-Nuremberg (FAU), 91054, Erlangen, Germany.
出版信息
Br J Dermatol. 2018 Sep;179(3):747-749. doi: 10.1111/bjd.16607. Epub 2018 Jun 26.
We present the case of a 77-year-old male patient with more than 50 basal cell carcinomas on the head and upper trunk. The patient did not respond to several lines of treatment, including surgery, imiquimod, retinoids, itraconazole and therapy with the hedgehog inhibitor vismodegib. The patient responded well to off-label therapy with the anti-programmed death-1 antibody pembrolizumab after four infusions.
我们报告了一例 77 岁男性患者，其头部和上半身有超过 50 个基底细胞癌。该患者对包括手术、咪喹莫特、维甲酸、伊曲康唑和 Hedgehog 抑制剂维莫德吉在内的多种治疗方案均无反应。在接受四次输注的抗程序性死亡-1 抗体派姆单抗（pembrolizumab）的标签外治疗后，该患者反应良好。
Zotero 插件